India's Sun Pharma Advanced falls as FDA declines approval to cancer treatment

Sun Pharma Advanced Research

12/02/2020 06:32

** Indian biopharmaceutical company's shares  SPRC.NS  fall
as much as 10.4% to 171.25 rupees after U.S. FDA declines to
approve SPRC's cancer treatment 
    ** SPRC says received a complete response letter (CRL) from
the regulator for its marketing application for its cancer
treatment Taclantis  urn:newsml:reuters.com:*:nFWN2AB0UL
    ** Taclantis is an injection that delivers paclitaxel, an
agent that kills cancer cells 
    ** Paclitaxel, sold under the brand name Taxol by
Bristol-Myers Squibb Co  BMY.N , is used to treat a number of
types of cancer, including breast, ovarian and lung cancer  
    ** SPRC did not disclose any of the concerns raised by the
FDA in the CRL
    ** "(SPRC) is reviewing the CRL and intends to work with the
U.S. FDA as soon as possible to address the concerns raised" -
SPRC statement (http://bit.ly/2UFs7bQ)
 
    ** SPRC stock fell 16.9% in 2019  



($1 = 71.2400 Indian rupees)

 (Reporting by Anuron Kumar Mitra in Bengaluru)
 ((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))